GenSight Biologics Reports its Cash Position as of March 31, 2019
(WorldNews Europe)

Paris, France, April 23, 2019, 7.30 am CET - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2019. Cash and cash equivalents GenSight...